TY - JOUR
T1 - Biomarkers for dementia in Latin American countries
T2 - Gaps and opportunities
AU - Investigación clínica
AU - Parra, Mario A.
AU - Orellana, Paulina
AU - Leon, Tomas
AU - Victoria, Cabello G.
AU - Henriquez, Fernando
AU - Gomez, Rodrigo
AU - Avalos, Constanza
AU - Damian, Andres
AU - Slachevsky, Andrea
AU - Ibañez, Agustin
AU - Zetterberg, Henrik
AU - Tijms, Betty M.
AU - Yokoyama, Jennifer S.
AU - Piña-Escudero, Stefanie D.
AU - Cochran, J. Nicholas
AU - Matallana, Diana L.
AU - Acosta, Daisy
AU - Allegri, Ricardo
AU - Arias-Suárez, Bianca P.
AU - Barra, Bernardo
AU - Behrens, Maria Isabel
AU - Brucki, Sonia M.D.
AU - Busatto, Geraldo
AU - Caramelli, Paulo
AU - Castro-Suarez, Sheila
AU - Contreras, Valeria
AU - Custodio, Nilton
AU - Dansilio, Sergio
AU - la Cruz-Puebla, Myriam De
AU - de Souza, Leonardo Cruz
AU - Diaz, Monica M.
AU - Duque, Lissette
AU - Farías, Gonzalo A.
AU - Ferreira, Sergio T.
AU - Guimet, Nahuel Magrath
AU - Kmaid, Ana
AU - Lira, David
AU - Lopera, Francisco
AU - Meza, Beatriz Mar
AU - Miotto, Eliane C.
AU - Nitrini, Ricardo
AU - Nuñez, Alberto
AU - O'Neill, Santiago
AU - Ochoa, John
AU - Pintado-Caipa, Maritza
AU - Resende, Elisa de Paula França
AU - Risacher, Shannon
AU - Rojas, Luz Angela
AU - Sabaj, Valentina
AU - Schilling, Lucas
N1 - Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2023/2
Y1 - 2023/2
N2 - Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.
AB - Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.
UR - https://www.scopus.com/pages/publications/85138014229
U2 - 10.1002/alz.12757
DO - 10.1002/alz.12757
M3 - Article
C2 - 36098676
AN - SCOPUS:85138014229
SN - 1552-5260
VL - 19
SP - 721
EP - 735
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 2
ER -
